Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.
Adult subjects aged 30 to 75 years at the time of screening/baseline.
Fitzpatrick skin types I-VI.
Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.
Willing and able to provide written informed consent form and photography release for research, publication, and/or commercial use.
Prior use of injectable treatments to the face within the past 12 months, including HA fillers and biostimulator injectables, i.e. calcium hydroxyapatite, poly-L-lactic acid (e.g., Sculptra, Radiesse), platelet-rich plasma (PRP), platelet-rich fibrin (PRF) Any facial surgical procedure (e.g., facelift, facial implants) within the past 12 months.
Use of neuromodulators (e.g., botulinum toxin) to the face or neck within 6 months prior to study enrollment or at any time during the study period.
Use of dermal fillers of any kind during the study period.
Use of at-home energy-based devices intended for rejuvenation or fibroblastic/collagen stimulation within 30 days prior to treatment and during the study period.
Single group
Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid
Other interventionObagi® Saypha® MagIQ™ Injectable Hyaluronic Acid is a sterile, biodegradable, homogenized and isotonic HA gel that uses an innovative crosslinking technology (MACRO Core Technology) to achieve a stable 3D HA matrix
Physician Global Aesthetic Improvement Scale (PGAIS)
Circle One: 1. Very Much Improved 2. Much Improved 3. Improved 4. No Change 5. Worse
Subject Global Aesthetic Improvement Scale (SGAIS)
Circle One: 1. Very Much Improved 2. Much Improved 3. Improved 4. No Change 5. Worse
Midface Volume Deficit Scale
Circle One: 0- None 1. Minimal 2. Mild 3. Moderate 4. Significant 5. Severe
Nasolabial Folds Wrinkle Severity Rating Scale
Circle One 1. Absent 2. Mild 3. Moderate 4. Severe 5. Extreme
Click on the lead sponsor to view all of their trials.
Goldman, Butterwick, Fitzpatrick and Groff
Lead sponsor
Obagi
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
